J-GLOBAL ID:200901000585377684
Update date: Aug. 10, 2024
Igarashi Ataru
イガラシ アタル | Igarashi Ataru
Research field (4):
Hygiene and public health (non-laboratory)
, Hygiene and public health (laboratory)
, Healthcare management, medical sociology
, Clinical pharmacy
Research keywords (1):
薬剤経済学
Research theme for competitive and other funds (13):
2023 - 2028 Dvelopment of a comprehensive cervical cancer early diagnosis system through community collaboration by promoting digital transformation in the era of women's active roles.
2023 - 2028 Dvelopment of a comprehensive cervical cancer early diagnosis system through community collaboration by promoting digital transformation in the era of women's active roles.
2024 - 2027 Research on identifying factors related to the onset/progression of diabetes and kidney diseases and estimating their impact on population health outcomes in Japan.
2021 - 2025 New valuable population based colorectal cancer screening: Including cost-effective analysis
2019 - 2022 The social costs of child maltreatment in Japan
2018 - 2021 Research on development of QOL evaluation and scoring algorithm using standard gamble method
2015 - 2019 Construction and development of the health technology assessment in the nursing science
2014 - 2018 Empirical study for accumulation of health-related QOL values for health economic evaluation
2015 - 2016 新材料を用いた終末期患者の臭気対策法-銅繊維による新しい消臭法の開発
2013 - 2015 Cost-effectiveness analysis of colorectal cancer screening using colonoscopy
2011 - 2015 Towards an appropriate application of new health technologies to the society - Development of a fair healthcare resource allocation system
2011 - 2013 Study of developing Japanese version of health literacy scales and fertility knowledge scale in health care
Haruka Maeda, Nobuo Saito, Ataru Igarashi, Masayuki Ishida, Mayumi Terada, Shingo Masuda, Ryosuke Osawa, Naoto Hosokawa, Kei Nakashima, Hiroshi Kamura, et al. Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS). Expert review of vaccines. 2024
Tsuyoshi Hamada, Hiroki Oyama, Ataru Igarashi, Yoshikuni Kawaguchi, Mihye Lee, Hiroki Matsui, Nobuaki Michihata, Yousuke Nakai, Kiyohide Fushimi, Hideo Yasunaga, et al. Optimal age to discontinue long-term surveillance of intraductal papillary mucinous neoplasms: comparative cost-effectiveness of surveillance by age. Gut. 2024
Saori Mishima, Yoichi Naito, Kiwamu Akagi, Naomi Hayashi, Akira Hirasawa, Tomoro Hishiki, Ataru Igarashi, Masafumi Ikeda, Shigenori Kadowaki, Hiroaki Kajiyama, et al. Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with DNA mismatch repair deficient (dMMR) tumors, third edition. International journal of clinical oncology. 2023. 28. 10. 1237-1258
Saori Mishima, Yoichi Naito, Kiwamu Akagi, Naomi Hayashi, Akira Hirasawa, Tomoro Hishiki, Ataru Igarashi, Masafumi Ikeda, Shigenori Kadowaki, Hiroaki Kajiyama, et al. Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors. International journal of clinical oncology. 2023. 28. 8. 941-955